1. Samavati, L, Uhal, B. ACE-2, much more than just a receptor for
SARS-CoV-2. Front Cell Infect Microbiol 2020; 10: 317eCollection
2020 PMID: 32582574.
2. Heurich, A, Hofmann-Winkler, H, Gierer, S et al. TMPRSS2 and
ADAM17 cleave ACE2 differentially and only proteolysis by
TMPRSS2 augments entry driven by the severe acute respiratory
syndrome coronavirus spike protein. J Virol 2014; 88: 1293–307
Epub 2013 Nov 13. PMID: 24227843; PMCID: PMC3911672.
3. Seyran, M, Takayama, K, Uversky, VN et al. The structural basis of
accelerated host cell entry by SARS-CoV-2†. FEBS J 2021; 288:
5010–20 PMID: 33264497.
4. Celik, I, Khan, A, Dwivany, FM et al. Computational prediction of
the effect of mutations in the receptor-binding domain on the
interaction between SARS-CoV-2 and human ACE2. Mol Divers
2022; 26: 3309–24 PMID: 35138508.
5. Oh, SJ, Shin, OS. SARS-CoV-2-mediated evasion strategies for
antiviral interferon pathways. J Microbiol 2022; 5: 1–10 PMID:
35122601; PMCID: PMC8817151.
6. Shah, M, Woo, HG. Omicron: a heavily mutated SARS-CoV-2
variant exhibits stronger binding to ACE2 and potently escapes
approved COVID-19 therapeutic antibodies. Front Immunol 2022;
12: 830527 PMID: 35140714; PMCID: PMC8819067.
7. Tatham, L, Sharp, J, Kijak, E et al. Lack of Ronapreve
(REGN-CoV; casirivimab and imdevimab) virological efficacy
against the SARS-CoV-2 omicron variant (B.1.1.529) in K18-hACE2
mice. bioRxiv [Preprint]. Jan 24:2022.01.23.4773972022; PMID:
35118468; PMCID: PMC8811901.
8. Planas, D, Saunders, N, Maes, P et al. Considerable escape of
SARS-CoV-2 omicron to antibody neutralization. Naturet 2022; 602:
671–75 PMID: 35016199.
9. Cameroni, E, Bowen, JE, Rosen, LE et al. Broadly neutralizing
antibodies overcome SARS-CoV-2 omicron antigenic shift. Nature
2022; 602: 664–70 PMID: 35016195.
10. Chan, KK, Dorosky, D, Sharma, P et al. Engineering human ACE2
to optimize binding to the spike protein of SARS coronavirus 2.
Science 2020; 369: 1261–5 Epub 2020 Aug 4. PMID: 32753553;
PMCID: PMC7574912.
11. Glascow, A, Glasgow, J, Limonta, D et al. Engineered ACE2
receptor traps potently neutralize SARS-CoV-2. Proc Natl Acad Sci
U S A 2020; 117: 28046–55.
12. Tanaka, S, Nelson, G, Olson, CA et al. An ACE2 triple decoy that
neutralizes SARS-CoV-2 shows enhanced affinity for virus variants.
Sci Rep 2021; 11: 12740 PMID: 34140558; PMCID: PMC8211782.
13. Maemura, T, Kuroda, M, Armbrust, T et al. Antibody-dependent
enhancement of SARS-CoV-2 infection is mediated by the IgG
receptors Fcγ RIIA and Fcγ RIIIA but does not contribute to
Downloaded from https://academic.oup.com/abt/article/6/1/59/6994056 by Kyoto University user on 15 May 2023
CONCLUSIONS
CONFLICT OF INTEREST STATEMENT
Neil Bodie DVM reports financial support was provided
by Paradigm Immunotherapeutics Inc. Bruce Uhal PhD
reports a relationship with Paradigm Immunotherapeutics Inc. that includes equity or stocks. Neil Bodie has
patent pending to Paradigm Immunotherapeutics. All other
authors have no conflicts to report.
74 Antibody Therapeutics, 2023
14.
15.
16.
17.
19.
20.
21.
22.
23.
24.
25.
26. Wilkinson, I, Anderson, S, Fry, J et al. Fc-engineered antibodies
with immune effector functions completely abolished. PLoS One
2021; 16: e0260954.
27. Dall’Acqua, WF, Woods, RM, Ward, ES et al. Increasing the
affinity of a human IgG1 for the neonatal fc receptor: biological
consequence. J Immunol 2002; 169: 5171–80.
28. Wang Q, Li Z, Ho J et al. . Resistance of SARS-CoV-2 omicron
subvariant BA.4.6 to Antibody neutralization. 2022 bioRxiv
Preprint, September 06, 2022.
29. Borrok, MJ, Mody, N, Lu, X et al. An "fc-silenced" IgG1 format
with extended half-life designed for improved stability. J Pharm Sci
2017; 106: 1008–17Epub 2017 Jan 3 PMID: 28057542.
30. Liu, P, Pan, Z, Gu, C et al. An Omalizumab biobetter antibody with
improved stability and efficacy for the treatment of allergic diseases.
Front Immunol 2020; 11: 596908 PMID: 33329588; PMCID:
PMC7728613.
31. Robbie, GJ, Criste, R, Dall’acqua, WF et al. A novel investigational
fc-modified humanized monoclonal antibody, motavizumab-YTE,
has an extended half-life in healthy adults. Antimicrob Agents
Chemother 2013; 57: 6147–53 Epub 2013 Sep 30. PMID: 24080653;
PMCID: PMC3837853.
32. Mackness, BC, Jaworski, JA, Boudanova, E et al. Antibody fc
engineering for enhanced neonatal fc receptor binding and
prolonged circulation half-life. MAbs 2019; 11: 1276–88 Epub 2019
Jul 18. PMID: 31216930; PMCID:
PMC6748615.
33. Halwe, S, Kupke, A, Vanshylla, K et al. Intranasal administration of
a monoclonal neutralizing antibody protects mice against
SARS-CoV-2 infection. Viruses 2021; 13: 1498 PMID: 34452363;
PMCID: PMC8402634.
34. Walters, BT, Jensen, PF, Larraillet, V et al. Conformational
destabilization of immunoglobulin G increases the low pH binding
affinity with the neonatal fc receptor. J Biol Chem 2016; 291:
1817–25 Epub 2015 Dec 1. PMID: 26627822; PMCID:
PMC4722460.
35. Amraei, R, Xia, C, Olejnik, J et al. Extracellular vimentin is an
attachment factor that facilitates SARS-CoV-2 entry into human
endothelial cells. Proc Natl Acad Sci U S A 2022; 119: e2113874119
PMID: 35078919.
36. Suzuki, T, Hashii, N, Tada, M et al. The influence of antibody
engineering on fc conformation and fc receptor binding properties:
analysis of FcRn-binding engineered antibodies and an fc fusion
protein. MAbs 2021; 13: 1923366 PMID: 34030575; PMCID:
PMC8158039.
Downloaded from https://academic.oup.com/abt/article/6/1/59/6994056 by Kyoto University user on 15 May 2023
18.
aberrant cytokine production by macrophages. MBio 2021; 12:
e0198721.
Sánchez-Zuno, GA, Matuz-Flores, MG, González-Estevez, G et al.
A review: antibody-dependent enhancement in COVID-19: the not
so friendly side of antibodies. Int J Immunopathol Pharmacol 2021;
35: 20587384211050199.
Junqueira, C, Crespo, Â, Ranjbar, S et al. Fcγ R-mediated
SARS-CoV-2 infection of monocytes activates inflammation. Nature
2022; 606: 576–84 PMID: 35385861.
Hou, YJ, Okuda, K, Edwards, CE et al. SARS-CoV-2 reverse
genetics reveals a variable infection gradient in the respiratory tract.
Cell 2020; 182: 429–446.e14 Epub 2020 May 27. PMID: 32526206;
PMCID: PMC7250779.
Zhang, J, Zhang, Y. A novel side-chain orientation dependent
potential derived from random-walk reference state for protein fold
selection and structure prediction. PLoS One 2010; 5: e15386 PMID:
21060880; PMCID: PMC2965178.
Zhou, H, Skolnick, J. Ab initio protein structure prediction using
chunk-TASSER. Biophys J 2007; 93: 1510–8 Epub 2007 May 11.
PMID: 17496016; PMCID: PMC1948038.
Zhou, HY, Zhou, YQ. Distance-scaled, finite ideal-gas reference
state improves structure-derived potentials of mean force for
structure selection and stability prediction. Protein Sci 2002; 11:
2714–26.
Starr, TN, Greaney, AJ, Hilton, SK et al. Deep mutational scanning
of SARS-CoV-2 receptor binding domain reveals constraints on
folding and ACE2 binding. Cell Sep 2020; 182: 1295–1310.e20Epub
2020 Aug 11 PMID: 32841599; PMCID: PMC7418704.
Tan, CW, Chia, WN, Qin, X et al. A SARS-CoV-2 surrogate virus
neutralization test based on antibody-mediated blockage of
ACE2-spike protein-protein interaction. Nat Biotechnol 2020; 38:
1073–8Epub 2020 Jul 23 PMID: 32704169.
Matsuyama, S, Nao, N, Shirato, K et al. Enhanced isolation of
SARS-CoV-2 by TMPRSS2-expressing cells. Proc Natl Acad Sci U S
A 2020; 117: 7001–3 Epub Mar 12. PMID: 32165541; PMCID:
PMC7132130.
Sano, E, Suzuki, T, Hashimoto, R et al. (2022) cell response analysis
in SARS-CoV-2 infected bronchial organoids. Commun Biol 2022; 5:
516 PMID: 35637255; PMCID: PMC9151746.
Ladel, S, Flamm, J, Zadeh, A et al. Allogenic fc domain-facilitated
uptake of IgG in nasal lamina Propria. Pharmaceutics 2018; 10: 107.
Zhu, Q, McLellan, JS, Kallewaard, NL et al. A highly potent
extended half-life antibody as a potential RSV vaccine surrogate for
all infants. Sci Transl Med 2017; 9: eaaj1928 PMID: 28469033.
...
論文の公開元へ
